Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Venous Thromboembolism-Epidemiology Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985

Details

EpiCast Report: Venous Thromboembolism-Epidemiology Forecast to 2026

Summary

Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in affected individuals. VTE can occur at any age, but it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), from 896,377 cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

GlobalData epidemiologists forecast the prevalent cases of VTE in the 7MM from 2016-2026 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific incidence of VTE, DVT, and PE in the 7MM. Additionally, they forecast the number of VTE attacks, medically ill discharges at risk of VTE, knee and hip replacements, recurrent VTE cases at one and 10 years, and VTE cases with cancer as comorbidity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of the diagnosed incident cases of VTE across these markets.

Scope

The Venous Thromboembolism (VTE) EpiCast Report provides an overview of the risk factors and global trends of VTE in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed incident cases of VTE, deep vein thrombosis, and pulmonary embolism segmented by sex and age (in five-year increments beginning at ages zero to four years and ending at 85 years and older) in these seven markets. Additionally, this report includes the number of VTE attacks, medically ill discharges at risk of VTE, primary total knee and hip replacements, recurrent VTE cases after one and 10 years, and diagnosed VTE cases with cancer as comorbidity.

The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The VTE EpiCast report will allow you to-

Develop business strategies by understanding the trends shaping and driving the global VTE market.

Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.

Identify the percentage of VTE cases with recurrence of VTE and percentage of VTE cases with cancer as comorbidity

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Venous Thromboembolism: Executive Summary 4

2.1 Related Reports 6

2.2 Upcoming Related Reports 6

3 Introduction 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 8

3.3 Global and Historical Trends 9

3.4 Forecast Methodology 11

3.4.1 Sources 11

3.4.2 Forecast Assumptions and Methods 13

3.5 Epidemiological Forecast for VTE (2016-2026) 24

3.5.1 Diagnosed Incident Cases of Pulmonary Embolism 24

3.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis 25

3.5.3 Diagnosed Incident Cases of VTE 26

3.5.4 Age-Specific Diagnosed Incident Cases of VTE 28

3.5.5 Sex-Specific Diagnosed Incident Cases of VTE 29

3.5.6 One- and 10-Year First Time Recurrent Cases of VTE 29

3.5.7 Number of VTE Cases with Cancer as Comorbidity 30

3.5.8 Number of VTE Attacks 31

3.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE 31

3.5.10 Number of Primary Total Knee Replacements and Revisions 32

3.5.11 Number of Hip Replacements 33

3.6 Discussion 34

3.6.1 Epidemiological Forecast Insight 34

3.6.2 Limitations of the Analysis 35

3.6.3 Strengths of the Analysis 35

4 Appendix 36

4.1 Bibliography 36

4.2 Physicians and Specialists Included in this Study 38

4.3 Primary Research-Key Opinion Leaders Interviewed for this Report 40

4.4 About the Authors 43

4.4.1 Epidemiologist 43

4.4.2 Reviewers 43

4.4.3 Global Director of Therapy Analysis and Epidemiology 44

4.4.4 Global Head and EVP of Healthcare Operations and Strategy 44

4.5 About GlobalData 44

4.6 Contact Us 45

4.7 Disclaimer 45


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, 2016 and 2026 5

Figure 2: 7MM, Number of VTE Attacks, Men and Women, All Ages, 2016 and 2026 5

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of PE, All Ages, Cases per 100,000 Population, 2016 10

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases per 100,000, 2016 11

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of PE and DVT, 2016 12

Figure 6: 7MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill. 2016 12

Figure 7: 7MM, Sources Used to Forecast Primary Total Knee Replacements and Hip Replacements. 2016 13

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of VTE, Men and Women, N 28

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of VTE, All Ages, N, 2016 29


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Venous Thromboembolism 8

Table 2: 7MM, Diagnosed Incident Cases of PE, Men and Women, All Ages, N, Select Years, 2016-2026 25

Table 3: 7MM, Diagnosed Incident Cases of DVT, Men and Women, All Ages, N, Select Years, 2016-2026 26

Table 4: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, N, Select Years, 2016-2026 27

Table 5: 7MM, One- and 10-Year Recurrent VTE Cases, Men and Women, All Ages, N, 2016 30

Table 6: Number of VTE Cases With Cancer Comorbidity, Men and Women, All Ages, N, 2016 and 2026 30

Table 7: 7MM, Number of VTE Attacks, Men and Women, All Ages, N, Select Years, 2016-2026 31

Table 8: 7MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Men and Women, Ages ?40 Years, N, 2016 32

Table 9: 7MM, Number of Primary Total Knee Replacements and Revisions, Men and Women, Ages ?15 Years, N, Select Years, 2016-2026 33

Table 10: 7MM, Number of Hip Replacements, Men and Women, Ages ?15 Years, N, Select Years, 2016-2026 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

EpiCast Report: Venous Thromboembolism-Epidemiology Forecast to 2026

Summary

Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in affected individuals. VTE can occur at any age, but it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), from 896,377 cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

GlobalData epidemiologists forecast the prevalent cases of VTE in the 7MM from 2016-2026 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific incidence of VTE, DVT, and PE in the 7MM. Additionally, they forecast the number of VTE attacks, medically ill discharges at risk of VTE, knee and hip replacements, recurrent VTE cases at one and 10 years, and VTE cases with cancer as comorbidity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of the diagnosed incident cases of VTE across these markets.

Scope

The Venous Thromboembolism (VTE) EpiCast Report provides an overview of the risk factors and global trends of VTE in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed incident cases of VTE, deep vein thrombosis, and pulmonary embolism segmented by sex and age (in five-year increments beginning at ages zero to four years and ending at 85 years and older) in these seven markets. Additionally, this report includes the number of VTE attacks, medically ill discharges at risk of VTE, primary total knee and hip replacements, recurrent VTE cases after one and 10 years, and diagnosed VTE cases with cancer as comorbidity.

The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The VTE EpiCast report will allow you to-

Develop business strategies by understanding the trends shaping and driving the global VTE market.

Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.

Identify the percentage of VTE cases with recurrence of VTE and percentage of VTE cases with cancer as comorbidity

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Venous Thromboembolism: Executive Summary 4

2.1 Related Reports 6

2.2 Upcoming Related Reports 6

3 Introduction 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 8

3.3 Global and Historical Trends 9

3.4 Forecast Methodology 11

3.4.1 Sources 11

3.4.2 Forecast Assumptions and Methods 13

3.5 Epidemiological Forecast for VTE (2016-2026) 24

3.5.1 Diagnosed Incident Cases of Pulmonary Embolism 24

3.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis 25

3.5.3 Diagnosed Incident Cases of VTE 26

3.5.4 Age-Specific Diagnosed Incident Cases of VTE 28

3.5.5 Sex-Specific Diagnosed Incident Cases of VTE 29

3.5.6 One- and 10-Year First Time Recurrent Cases of VTE 29

3.5.7 Number of VTE Cases with Cancer as Comorbidity 30

3.5.8 Number of VTE Attacks 31

3.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE 31

3.5.10 Number of Primary Total Knee Replacements and Revisions 32

3.5.11 Number of Hip Replacements 33

3.6 Discussion 34

3.6.1 Epidemiological Forecast Insight 34

3.6.2 Limitations of the Analysis 35

3.6.3 Strengths of the Analysis 35

4 Appendix 36

4.1 Bibliography 36

4.2 Physicians and Specialists Included in this Study 38

4.3 Primary Research-Key Opinion Leaders Interviewed for this Report 40

4.4 About the Authors 43

4.4.1 Epidemiologist 43

4.4.2 Reviewers 43

4.4.3 Global Director of Therapy Analysis and Epidemiology 44

4.4.4 Global Head and EVP of Healthcare Operations and Strategy 44

4.5 About GlobalData 44

4.6 Contact Us 45

4.7 Disclaimer 45


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, 2016 and 2026 5

Figure 2: 7MM, Number of VTE Attacks, Men and Women, All Ages, 2016 and 2026 5

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of PE, All Ages, Cases per 100,000 Population, 2016 10

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases per 100,000, 2016 11

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of PE and DVT, 2016 12

Figure 6: 7MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill. 2016 12

Figure 7: 7MM, Sources Used to Forecast Primary Total Knee Replacements and Hip Replacements. 2016 13

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of VTE, Men and Women, N 28

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of VTE, All Ages, N, 2016 29


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Venous Thromboembolism 8

Table 2: 7MM, Diagnosed Incident Cases of PE, Men and Women, All Ages, N, Select Years, 2016-2026 25

Table 3: 7MM, Diagnosed Incident Cases of DVT, Men and Women, All Ages, N, Select Years, 2016-2026 26

Table 4: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, N, Select Years, 2016-2026 27

Table 5: 7MM, One- and 10-Year Recurrent VTE Cases, Men and Women, All Ages, N, 2016 30

Table 6: Number of VTE Cases With Cancer Comorbidity, Men and Women, All Ages, N, 2016 and 2026 30

Table 7: 7MM, Number of VTE Attacks, Men and Women, All Ages, N, Select Years, 2016-2026 31

Table 8: 7MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Men and Women, Ages ?40 Years, N, 2016 32

Table 9: 7MM, Number of Primary Total Knee Replacements and Revisions, Men and Women, Ages ?15 Years, N, Select Years, 2016-2026 33

Table 10: 7MM, Number of Hip Replacements, Men and Women, Ages ?15 Years, N, Select Years, 2016-2026 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS